Pfizer Closes $9.2 Billion Acquisition of Metsera, Bolstering Next-Gen Obesity and Cardiometabolic Pipeline

On November 13, Pfizer announced that it had successfully completed the acquisition of Metsera. Metsera is a biopharmaceutical company dedicated to accelerating the development of next-generation treatments for obesity and cardiometabolic diseases.

Pfizer Acquires All Outstanding Common Shares of Metsera for $65.60 per Share in Cash, Reflecting an Enterprise Value of Approximately $7 Billion; Additionally, Each Share is Eligible for a Contingent Value Right (CVR) of Up to $20.65 per Share (Approximately $2.2 Billion Total), Tied to Three Specific Clinical and Regulatory Milestones. The Total Transaction Value is Approximately $9.2 Billion. Upon Completion of the Transaction, Metsera Will Become a Wholly Owned Subsidiary of Pfizer, and Its Common Stock Will Cease Trading on the Nasdaq Global Select Market.

Through this acquisition, Pfizer has added a series of potential candidate drugs that are highly complementary to its existing internal medicine pipeline, including:

• MET-097i: An injectable GLP-1 receptor agonist administered once weekly or monthly, soon to enter Phase III clinical trials;

  
  

• MET-233i: A once-monthly amylin analog is currently in Phase I evaluation as monotherapy and in combination with MET-097i;

  
  

• Oral GLP-1 receptor agonist: in Phase I clinical stage;

  
  

• Other preclinical Nutrient-Stimulating Hormone (NuSH) therapies.

Pfizer Chairman and CEO Albert Bourla stated: "This strategic milestone is not just a transaction, but a well-considered investment in the future of medicine. By acquiring Metsera, we are channeling our resources into one of the most impactful and fastest-growing therapeutic areas, establishing ourselves as a defining force in this field. We look forward to deeply integrating Metsera's innovative portfolio with Pfizer's global development, manufacturing, and commercialization systems, and working alongside Metsera's talented new colleagues to advance and accelerate the delivery of these important candidate therapies to patients worldwide."